Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
NRXP NRX Pharmaceuticals
1.2500.0000.00%
Close
02/03 16:00 ET
1.2500.0000.00%
Post Mkt Price 02/03 16:08 ET
High
1.270
Open
1.240
Turnover
167.72K
Low
1.200
Pre Close
1.250
Volume
134.89K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
NRX Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
NRX Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
H.C. Wainwright Sticks to Their Buy Rating for NRX Pharmaceuticals (NRXP)
NRX Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/02/2023 63.93% HC Wainwright & Co. → $2 Reiterates → Buy 11/09/2022 227.87% Ascendiant Capital → $4 Ini
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $2 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $2 price target.
NRx Pharmaceuticals Reports Recommendations of DSMB for NRX-101 Trial
NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients With Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior
H.C. Wainwright Remains a Buy on NRX Pharmaceuticals (NRXP)
NRx Pharma Gains on FDA Comments Regarding Lead Asset
NRx Pharmaceuticals Reaches Alignment With FDA on Manufacturing Plan
NRx Pharmaceuticals Provided Progress Update on Interactions With the FDA Regarding Path to NDA Submission for NRX-101; Said It Appears That NRX Pharmaceuticals Has Reached Alignment With The Fda Regarding Its Proposed Registration Manufacturing Plan.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced that it had a meeting and a wri
Company Overview
More
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
CEO： Mr. Stephen H. Willard
Market： NASDAQ
Listing Date： 12/01/2017
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet